BiotechTube

Molnupiravir 200 mg + Molnupiravir 400 mg + Molnupiravir 800 mg + Placebo (PBO)

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2 Infection, COVID-19

Conditions

SARS-CoV-2 Infection, COVID-19

Trial Timeline

Jun 19, 2020 → Feb 21, 2021

NCT ID
NCT04405570

About Molnupiravir 200 mg + Molnupiravir 400 mg + Molnupiravir 800 mg + Placebo (PBO)

Molnupiravir 200 mg + Molnupiravir 400 mg + Molnupiravir 800 mg + Placebo (PBO) is a phase 2 stage product being developed by Merck for SARS-CoV-2 Infection, COVID-19. The current trial status is completed. This product is registered under clinical trial identifier NCT04405570. Target conditions include SARS-CoV-2 Infection, COVID-19.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04405570Phase 2Completed

Competing Products

20 competing products in SARS-CoV-2 Infection, COVID-19

See all competitors
ProductCompanyStageHype Score
CT-P59CelltrionPhase 1
33
CT-P63 + PlaceboCelltrionPhase 1
33
CT-P59 + CT-P59 + Placebo + CT-P59 + PlaceboCelltrionPhase 2/3
65
CT-P59 + PlaceboCelltrionPhase 1
33
S-268019-b + PlaceboShionogiPhase 3
77
S-217622 + PlaceboShionogiPhase 3
77
S-217622 + PlaceboShionogiPhase 3
77
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77
Nitric OxideGlenmark PharmaceuticalsPhase 3
77
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
52
EvusheldAstraZenecaPre-clinical
23
Biological: AZD3152 + Biological: PlaceboAstraZenecaPhase 2
52
AZD5156 (Parent study Sentinel Safety Cohort) + Placebo (Parent study Sentinel Safety Cohort) + EVUSHELD™ (Parent study Main Cohort) + AZD3152 (Parent study Main Cohort) + Placebo (Parent study Main Cohort) + AZD3152 (Sub-study) + AZD7442 - EVUSHELD™ (Sub-study) + AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152AstraZenecaPhase 2/3
65
EVUSHELDAstraZenecaPre-clinical
23
AZD1222AstraZenecaApproved
85
AZD3152 (Cohort 1) + Placebo (Cohort 1) + AZD3152 (Cohort 2) + Placebo (Cohort 2) + AZD3152 (Cohort 3) + Placebo (Cohort 3)AstraZenecaPhase 1
33
EVUSHELDAstraZenecaPre-clinical
23
AZD7442AstraZenecaPhase 1
33
EVUSHELDAstraZenecaPre-clinical
23
Tocilizumab (TCZ) + PlaceboRochePhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85